RxDoctor Payments Data

Ramin Rabbani, MD

Interventional Cardiology · Laguna Hills, CANPI 1518962539

Payments from drug & device makers

$6,350in general payments, 2019–2025

Across 302 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$942
  • Johnson & Johnson$918
  • Amgen$761
  • E.r. Squibb & Sons, L.L.C.$457
  • Biotronik Inc.$408
  • AstraZeneca$404
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,21798%
  • Education$1332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,350 in reported general payments places this provider in the 35th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$677,325
Medicare patients
1,521
Services billed
8,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban458$550,307
XareltoRivaroxaban230$298,575
Repatha SureclickEvolocumab162$109,160
Praluent PenAlirocumab115$77,082
EntrestoSacubitril/Valsartan41$42,583
MultaqDronedarone Hcl19$29,777
Metoprolol Succinate638$9,112
Diltiazem 24hr Er (Cd)Diltiazem Hcl217$7,781
Losartan Potassium457$5,086
Rosuvastatin Calcium300$4,468
Flecainide Acetate79$4,443
Atorvastatin Calcium376$3,709
Amlodipine Besylate398$3,426
Hydralazine Hcl191$3,198
Isosorbide Mononitrate ErIsosorbide Mononitrate178$2,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$335$550,307458 claims
Johnson & JohnsonXarelto$918$298,575230 claims
NovartisEntresto$942$42,58341 claims
Sanofi-aventis U.S. LLCMultaq$240$29,77719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →